Prostate-specific membrane antigen (PSMA) is an excellent prostate cancer target for theranostic applications. Many imaging agents showing high sensitivity or specificity for PSMA-expressing tissues have been developed ([@bib1]). Some have been labeled with therapeutic radionuclides (i.e., ^177^Lu and ^225^Ac) and have had success in treating castration-resistant metastatic prostate cancer ([@bib2],[@bib3]). The activity administered to patients is limited by toxicity to normal organs; high uptake is observed in the lacrimal glands, parotid glands, submandibular glands, and renal cortex ([@bib4]). The potential side effects of higher doses include hematotoxicity, xerostomia, and renal dysfunction ([@bib2],[@bib3]). In particular, xerostomia with α-emitters is so severe that patients have discontinued treatment ([@bib5]). A means of decreasing this toxicity without affecting tumor uptake would allow administration of greater activity with presumably greater tumoricidal effect.

Different pharmaceuticals, including 2-(phosphonomethyl)pentanedioic acid (PMPA), a PSMA inhibitor, have been explored for nephroprotection ([@bib6],[@bib7]). PMPA displaced renal activity of a PSMA radiotherapeutic in cancer models, but this was generally accompanied by a reduction in tumor uptake ([@bib6],[@bib7]). Mannitol infusion reduced renal uptake of ^68^Ga-PSMA-11 ([@bib8]), but its effect on tumor uptake requires further investigations. Botulinum toxin was administered to the parotid gland of a patient and significantly decreased PSMA-ligand uptake ([@bib9]). Although this procedure is promising, it is invasive and costly and may affect salivary gland function for weeks. In this study, we investigated monosodium glutamate (MSG) for reducing uptake of ^68^Ga-PSMA-11 in the salivary glands and kidneys in LNCaP tumor--bearing mice. MSG is a well-studied food additive and can stimulate salivary flow ([@bib10],[@bib11]). Although PSMA is expressed in the salivary glands and kidneys, part of PSMA-ligand uptake in salivary glands may be due to off-target binding, as uptake is not observed in human studies with the radiolabeled J591 monoclonal antibody ([@bib12]--[@bib14]). Because many PSMA ligands integrate glutamate for binding to PSMA, we hypothesized that MSG could reduce nonspecific accumulation in noncancerous tissues.

MATERIALS AND METHODS
=====================

^68^Ga-PSMA-11 Radiolabeling
----------------------------

The standard and radiolabeling precursor were purchased from ABX Advanced Biochemical Compounds. Radiolabeling was performed as previously published ([@bib15]).

Cell Culture
------------

LNCaP prostate adenocarcinoma cells (ATCC) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Sigma-Aldrich), penicillin (100 IU/mL), and streptomycin (100 μg/m) (Life Technologies) in a humidified incubator (37°C, 5% CO~2~).

Competition Binding Assay
-------------------------

LNCaP cells were washed with phosphate-buffered saline (PBS) and harvested by trypsinization. Cells (200,000/well) were seeded onto a 24-well poly-[d]{.smallcaps}-lysine--coated plate for 48 h. Growth medium was replaced with PBS buffer (with 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, 2% bovine serum albumin, pH 7.5) 1 h before the study. ^18^F-DCFPyL (0.1 nM), synthesized according to published procedures ([@bib16]), was added to wells containing MSG (1 × 10^−2^ to 1.3 × 10^−7^ M), in triplicate. The assays were incubated for 1 h at 37°C with agitation. After aspiration, cells were washed twice with cold 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid-buffered saline. To harvest cells, 400 μL of trypsin were added to each well. Samples were counted using a Wizard2 2480 (PerkinElmer) automatic γ-counter. Binding affinity (K~i~) was calculated using nonlinear regression in Prism 7 (GraphPad Software) with a dissociation constant of 0.49 nM for ^18^F-DCFPyL.

PET Imaging and Biodistribution
-------------------------------

Animal experiments were approved by the Animal Ethics Committee of the University of British Columbia. Immunodeficient NOD.Cg-*Prkdc*^*scid*^*Il2rg*^*tm1Wjl*^/SzJ male mice were obtained in-house. Mice were subcutaneously inoculated with 5 × 10^6^ LNCaP cells (100 μL; 1:1 PBS/Matrigel \[Corning\]), with tumors grown for 4--6 wk. Mice were injected intraperitoneally with MSG (657, 329, or 164 mg/kg) or PBS. After 15 min, mice were anesthetized with isoflurane (2.5% in a 2.0 L/min flow of O~2~) and injected intravenously with ^68^Ga-PSMA-11 (5.34 ± 0.95 MBq for PET/CT, 1.86 ± 0.71 MBq for biodistribution studies).

PET/CT imaging was conducted on a Siemens Inveon small-animal PET/CT device. After a 45-min uptake period, the mice were sedated with isoflurane and placed on the scanner. Body temperature was maintained by a heating pad. A CT scan was obtained for localization and attenuation correction (80-kV tube voltage, 500-μA current, 3 bed positions, 34% overlap, and 220° of continuous rotation). This scan was followed by a 10-min PET acquisition 1 h after injection of ^68^Ga-PSMA-11. PET imaging data were acquired in list mode, reconstructed using 3-dimensional ordered-subsets expectation maximization (2 iterations) followed by a fast maximum a priori algorithm (18 iterations) with CT-based attenuation correction. Images were analyzed using Inveon Research Workplace software (Siemens Healthineers).

For biodistribution studies, 1 h after radiopharmaceutical injection, the mice were anesthetized with isoflurane and euthanized by CO~2~ inhalation. Blood was collected via cardiac puncture. Organs and tissues were harvested, rinsed with PBS, blotted dry, and weighed. The radioactivity in tissues was assayed by γ-counter and expressed as percentage injected dose per gram of tissue (%ID/g).

Statistical Analysis
--------------------

Analysis was performed with R, version 3.4.0 (R Foundation for Statistical Computing). Outliers identified by one round of the Grubb test (α \< 0.01) were removed. When data distribution was normal according to the Shapiro--Wilk test (α \< 0.05), groups were compared using the Welch *t* test or the Wilcoxon rank sum test. The Holm correction was used for multiple comparisons. The significance level was an α value of less than 0.05. PBS controls repeated for each experiment (different batches of radiotracer) were aggregated in a single group for analysis.

RESULTS
=======

^68^Ga-PSMA-11 was synthesized in 66.3% ± 8.8% decay-corrected radiochemical yields with more than 99% radiochemical purity and 82.6 ± 44.3 GBq/μmol molar activity (*n* = 6).

Biodistribution results are shown in [Figure 1](#fig1){ref-type="fig"} and Supplemental Table 1 (supplemental materials are available at [http://jnm.snmjournals.org](http://jnm.snmjournals.org/)). There were no statistical differences for tumor uptake between the 4 groups, at 8.42 ± 1.40 %ID/g in the 657 mg/kg group, 7.19 ± 0.86 %ID/g in the 329 mg/kg group, 8.20 ± 2.44 %ID/g in the 164 mg/kg group, and 8.67 ± 1.97 %ID/g in the PBS group. Kidney uptake was significantly lower in the 657 mg/kg group (85.8 ± 24.2 %ID/g) than in the groups given 329 mg/kg (159 ± 26.2 %ID/g), 164 mg/kg (211 ± 27.4 %ID/g), and PBS (182 ± 33.5 %ID/g) (*P* \< 0.001). The difference between the 329 and 164 mg/kg groups was significant (*P* \< 0.05), but not when they were, respectively, compared with PBS. Salivary gland uptake was lower in the 657 mg/kg (3.72 ± 2.12 %ID/g) and 329 mg/kg (5.74 ± 0.62 %ID/g) groups than in the PBS group (10.04 ± 2.52 %ID/g); *P* \< 0.01. There were no significant differences between the 164 mg/kg (14.2 ± 4.27 %ID/g) and PBS groups, or between the 657 and 329 mg/kg groups. Muscle uptake was generally lower in MSG-treated groups.

![Biodistribution of ^68^Ga-PSMA-11 in selected organs at 1 h after injection. Mice received MSG (657, 329, or 164 mg/kg) or PBS intraperitoneally 15 min before tracer administration.](1865fig1){#fig1}

PET imaging studies were performed on mice preinjected with PBS or a 657 mg/kg dose of MSG ([Fig. 2](#fig2){ref-type="fig"}). High uptake in LNCaP tumors was observed, with the remainder of the radioactivity cleared through the renal pathway. Compared with the PBS group, MSG-treated mice showed lower uptake in the salivary glands and faster excretion (more urinary output). The difference in clearance rates led to higher-contrast images for MSG-treated mice.

![PET maximum-intensity projections of 4 mice with ^68^Ga-PSMA-11 at 1 h after injection. LNCaP tumor--bearing mice received PBS (A) or MSG (B) (657 mg/kg) intraperitoneally 15 min before tracer administration. bl = bladder; k = kidney; sg = salivary glands; t = tumor.](1865fig2){#fig2}

The binding affinity (K~i~ value) of MSG to PSMA was 0.90 ± 0.58 mM (*n* = 3), as measured using a cell-based competition assay with ^18^F-DCFPyL ([Fig. 3](#fig3){ref-type="fig"}).

![Representative competition binding assay for MSG against ^18^F-DCFPyL in LNCaP cells. K~i~ value for this assay was 0.95 mM.](1865fig3){#fig3}

DISCUSSION
==========

The development of PSMA radiotheranostic agents has had a significant impact on prostate cancer management ([@bib17]). Small-molecule inhibitors were developed as alternatives to monoclonal antibodies, primarily for their fast targeting properties and clearance profiles ([@bib17]). However, radiolabeled PSMA inhibitors show undesired uptake in salivary glands ([@bib17]). Although this does not hinder diagnostic interpretation, it imposes a limit on the maximum-tolerable dose for therapy.

We investigated the effect of MSG on ^68^Ga-PSMA-11 salivary uptake. The doses of MSG chosen for this study corresponded to one tenth, twentieth, and fortieth of the median lethal dose for mice ([@bib18]).

We observed a significant decrease in kidney uptake (50% for 657 mg/kg) and salivary uptake (43%--53% for 329 and 657 mg/kg) of ^68^Ga-PSMA-11 for MSG-treated mice compared with control. Uptake in kidney and salivary glands was higher for the 164 mg/kg group than for the PBS group, but this difference was not statistically significant. Notably, tumor uptake did not significantly differ among the 4 groups. At more than 329 mg/kg, MSG blocked renal and salivary uptake without affecting tumor uptake. PET imaging corroborated the biodistribution results, notwithstanding enhanced contrast for MSG-treated mice, which can be explained by accelerated clearance of ^68^Ga-PSMA-11 or reduced nonspecific accumulation.

Kratochwil et al. demonstrated that PMPA can reduce renal uptake of ^125^I-MIP-1095 without affecting LNCaP tumor uptake; however, a 16-h latency period was required for tracer binding and clearance before PMPA administration ([@bib6]). Chatalic et al. showed that coinjection of PMPA with ^111^In/^177^Lu-PSMA I&T could improve the tumor-to-kidney absorbed dose ratio, but this improvement was accompanied by a reduction in tumor uptake ([@bib7]). The high affinity of PMPA to PSMA (reported K~i~, 0.28 nM) may complicate dose optimization ([@bib19]). Conversely, MSG has poor binding affinity to PSMA (K~i~, 0.90 ± 0.58 mM), which may benefit this application.

Although MSG has been linked to headaches and "Chinese restaurant syndrome," human studies have shown MSG to be safe; based on a no-adverse-event limit of 3,200 mg/kg/d for neurodevelopmental toxicity, the European Food Safety Authority advised that a daily intake of 30 mg/kg is acceptable ([@bib18],[@bib20]). Fernstrom administered a single 12.7-g dose of MSG orally to humans without side effects, with a return of plasma glutamate levels to baseline after 3 h ([@bib21]). The MSG quantity required to achieve effective off-target blocking of ^68^Ga-PSMA-11 in humans is not known, as human physiology may vary. Whether sufficient quantities can be practically administered to human subjects will require further investigation.

CONCLUSION
==========

MSG can decrease salivary and renal uptake of ^68^Ga-PSMA-11 without affecting tumor uptake in mice, presumably by competing with off-target binding sites. This effect could potentially be used to increase the therapeutic index of glutamate-based radioligands. Further work is needed to assess whether this blocking effect is sufficiently durable to protect these organs from longer-lived radioisotopes, to understand the mechanism of action and to assess if the same effect can be translated to humans.
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